Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission
Open Access
- 29 October 2021
- journal article
- research article
- Published by Springer Nature in Molecular Psychiatry
- Vol. 27 (2) , 831-839
Abstract
Behavioral conditioning and expectation can have profound impact on animal and human physiology. Placebo, administered under positive expectation in clinical trials, can have potent effects on disease pathology, obscuring active medications. Emerging evidence suggests placebo-responsive neurotransmitter systems (e.g., endogenous opioid) regulate immune function by manipulating inflammatory proteins including IL-18, a potent pro-inflammatory, nociceptive cytokine implicated in pathophysiology of various diseases. Validation that neuroimmune interactions involving brain μ-opioid receptor (MOR) activity and plasma IL-18 underlie placebo analgesic expectation could have widespread clinical applications. Unfortunately, current lack of mechanistic clarity obfuscates clinical translation. To elucidate neuroimmune interactions underlying placebo analgesia, we exposed 37 healthy human volunteers to a standardized pain challenge on each of 2 days within a Positron Emission Tomography (PET) neuroimaging paradigm using the MOR selective radiotracer, 11C-Carfentanil (CFN). Each day volunteers received an intervention (placebo under analgesic expectation or no treatment), completed PET scanning, and rated their pain experience. MOR BPND parametric maps were generated from PET scans using standard methods. Results showed placebo reduced plasma IL-18 during pain (W74 = −3.7, p < 0.001), the extent correlating with reduction in pain scores. Placebo reduction in IL-18 covaried with placebo-induced endogenous opioid release in the left nucleus accumbens (T148 = 3.33; puncorr < 0.001) and left amygdala (T148 = 3.30; puncorr < 0.001). These findings are consistent with a modulating effect of placebo (under analgesic expectation in humans) on a potent nociceptive, pro-inflammatory cytokine (IL-18) and underlying relationships with endogenous opioid activity, a neurotransmitter system critically involved in pain, stress, and mood regulation.Keywords
This publication has 75 references indexed in Scilit:
- Placebo Effects on the Immune Response in Humans: The Role of Learning and ExpectationPLOS ONE, 2012
- Catechol-O-Methyltransferase val158met Polymorphism Predicts Placebo Effect in Irritable Bowel SyndromePLOS ONE, 2012
- Nonconscious activation of placebo and nocebo pain responsesProceedings of the National Academy of Sciences, 2012
- Active Albuterol or Placebo, Sham Acupuncture, or No Intervention in AsthmaNew England Journal of Medicine, 2011
- Behavioural conditioning as the mediator of placebo responses in the immune systemPhilosophical Transactions of the Royal Society B: Biological Sciences, 2011
- Traditional Chinese acupuncture and placebo (sham) acupuncture are differentiated by their effects on μ-opioid receptors (MORs)NeuroImage, 2009
- Neurobiological Mechanisms of Placebo ResponsesAnnals of the New York Academy of Sciences, 2009
- From inflammation to sickness and depression: when the immune system subjugates the brainNature Reviews Neuroscience, 2008
- Placebo effects on human μ-opioid activity during painProceedings of the National Academy of Sciences, 2007
- Pronociceptive and Antinociceptive Effects of Estradiol through Endogenous Opioid Neurotransmission in WomenThe Journal of Neuroscience, 2006